GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™, to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™, to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™, to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™, to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.